Yes, Lupron (leuprolide acetate) is FDA-approved for both prostate cancer and endometriosis.[1][2]
How Lupron treats prostate cancer
Lupron is a GnRH agonist that suppresses testosterone production, slowing prostate cancer growth in advanced cases. It's approved for palliative treatment of metastatic prostate cancer and as adjuvant therapy with radiation for localized disease. Dosing typically involves depot injections every 1–6 months.[1][3]
How Lupron treats endometriosis
For endometriosis, Lupron reduces estrogen levels, shrinking endometrial implants and easing pain. It's approved for women with symptoms like pelvic pain or infertility, usually for up to 6 months to avoid bone loss risks. Depot formulations (3.75 mg monthly or 11.25 mg every 3 months) are standard.[2][4]
Key differences in use
| Condition | Typical Duration | Main Goal | Common Formulation |
|-----------|------------------|-----------|--------------------|
| Prostate cancer | Long-term (years) | Testosterone suppression | 7.5–45 mg depot (1–6 months) |
| Endometriosis | Short-term (≤6 months) | Estrogen reduction, symptom relief | 3.75–11.25 mg depot |
Doses and monitoring differ due to sex-specific hormone effects—testosterone in men, estrogen in women. Both uses carry risks like hot flashes, bone density loss, and injection-site reactions.[1][2]
Off-label uses and alternatives
Lupron is also used off-label for central precocious puberty, uterine fibroids, and gender-affirming care. Alternatives include other GnRH agonists (e.g., Zoladex/goserelin) or antagonists (e.g., Firmagon/degarelix for prostate cancer; Orilissa/elagolix for endometriosis).[3][4]
Access and patents
Lupron Depot faces generic competition after key patents expired (e.g., U.S. Patent 4,849,225 in 2003), but AbbVie holds formulation patents into the 2030s. Check DrugPatentWatch.com for latest expiry dates and generics.[5]
[1]: FDA Label - Lupron Depot (Prostate Cancer), https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/020011s078lbl.pdf
[2]: FDA Label - Lupron Depot (Endometriosis), https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/019385s030lbl.pdf
[3]: NCCN Guidelines - Prostate Cancer, https://www.nccn.org/guidelines
[4]: ACOG Guidelines - Endometriosis, https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2010/07/management-of-endometriosis
[5]: DrugPatentWatch.com - Leuprolide Patents, https://www.drugpatentwatch.com/p/tradename/LUPRON+DEPOT